WO2021029443A1 - Composition hémostatique locale - Google Patents

Composition hémostatique locale Download PDF

Info

Publication number
WO2021029443A1
WO2021029443A1 PCT/KP2020/000050 KP2020000050W WO2021029443A1 WO 2021029443 A1 WO2021029443 A1 WO 2021029443A1 KP 2020000050 W KP2020000050 W KP 2020000050W WO 2021029443 A1 WO2021029443 A1 WO 2021029443A1
Authority
WO
WIPO (PCT)
Prior art keywords
hemostatic composition
local hemostatic
hemostatic
local
bleeding
Prior art date
Application number
PCT/KP2020/000050
Other languages
English (en)
Inventor
Chun Mok RIM
Original Assignee
RIM, Chol Hak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIM, Chol Hak filed Critical RIM, Chol Hak
Priority to CN202080058658.1A priority Critical patent/CN114269350B/zh
Publication of WO2021029443A1 publication Critical patent/WO2021029443A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • This invention relates to a local hemostatic composition
  • a local hemostatic composition comprising N-acetylglucosamine (GlcNAc).
  • the amount of blood in a human body is about 8% of the body weight. If a person bleeds as much as 20% or more of the total blood amount, the person falls in shock or dies.
  • medicaments which constrict the local blood vessel and promote coagulation of blood by astriction or oxidation, coagulation of protein, etc. were selected and used.
  • Adrenaline hydrogen peroxide, potassium permanganate, thrombin solution, hypertonic salt solution, calcium chloride, ferric chloride, aluminium sulphate, alum, tannin, silver nitrate, lead acetate and the like are typical of the local hemostatic agents.
  • a zeolite hemostatic which stops bleeding by coagulating protein, achieves the haemostatic effect by coagulating plasma protein and ambient tissues while generating heat (usually 60 ⁇ 70 ° C) through reaction with blood. But, its disadvantage is that it can be applied to stop only small bleeding and requires the aftertreatment.
  • Chinese patent CN103721247A disclosed a kind of compound hemostatic powder made of extract from radix gynural, I -collagen, chitosan, gelatin and the like. It disclosed that the hemostatic agent was powder and had various functions such as hemostasis, antibacterium, alleviation of pain and promotion of wound healing.
  • Chinese patent CN104436279A disclosed manufacturing process of medical antibacterial bandage which had hemostatic function and included chitosan, chitin or hydroxychitosan and auxiliary material including calcium chloride and glycerin. It disclosed that this medical antibacterial bandage not only had a strong effect of hemostasis without depending on general hemostatic mechanism, but also could avoid the thrombosis without having influence on the function and number of blood platelet. Besides, it disclosed that it had antibacterial and anti-infective functions, and could be removed easily.
  • Chinese patent CN10447457A disclosed a manufacturing process of amylum complex polysaccharide hemostatic powder. It disclosed that the hemostatic powder had a good effect of hemostasis and could readily decompose itself in human body as well as it prevented conglutination. Also, it disclosed that its manufacturing process is simple and the manufacturing cost is low.
  • the above-mentioned hemostatic agents including the natural biopolymers have some defects.
  • hemostatic agents don’t have good interaction with wounds because chitosan is insoluble in water, and they don’t have satisfactory antibacterial function and promotion unction of wound healing. Most importantly, the hemostatic agents including chitosan are not effective in stopping profuse arterial bleeding and the hemostatic time is relatively long.
  • the solid-foam hemostatic agent may be applied to only abdominal bleeding and the hemostatic sponge may be applied to the only bleeding of arms or legs.
  • the hemostatic sponge cannot be applied to severed wound such as severed arm or leg because there is no fulcrum.
  • the form of medicament has a great influence on the hemostatic effect.
  • hemostatic agents such as sponge, foam, powder, ointment, film, etc. have been used until now.
  • the drawback of the powdered hemostatic agent is that in case of profuse arterial hemorrhage, the powders don’t adhere sufficiently to wound surface because they are scattered by large bleeding and high pressure thereof.
  • the sponge or band type of hemostatic agent is limited in position or form of wound because it cannot be effectively applied to wide or deep wounds.
  • the foamy hemostatic agent can be only applied to the bleeding in the cavities such as the abdominal cavity, the thoracic cavity or the true pelvis cavity.
  • the prior hemostatic agents can easily stop small bleeding such as capillary hemorrhage, but can not stop profuse bleeding by injury or severance of abdominal aorta or arteria femoralis.
  • the prior hemostatic agents can not stop bleeding in water.
  • the purpose of the present invention is to provide the local hemostatic compositions which can promptly stop not only capillary bleeding but also profuse arterial and venous bleeding, which don’t require the aftertreatment operation, and which can stop the bleeding in water.
  • the purpose of the present invention is to provide the local hemostatic compositions which can make a good contact with the wound regardless of bleeding place and the form of wound.
  • the present invention relates to a local hemostatic composition comprising N-acetylglucosamine and use thereof.
  • the local hemostatic composition of the present invention is a hemostatic agent which can immediately stop bleeding in local region, such as all of the traumatic hemorrhage including profuse arterial hemorrhage, not to mention capillary hemorrhage, intraoperative hemorrhage and hemorrhage of alimentary canal and the like.
  • N-acetylglucosamine (GlcNAc) mentioned in the invention refers to N-acetyl- D-glucosamine.
  • N-acetylglucosamine reacts with blood plasma to make the membranous structure which can be adhered to organs and tissues.
  • the present invention in a first aspect, provides a local hemostatic composition comprising N-acetylglucosamine in the range from 0.5% to 50% w/v and distilled water as a solvent.
  • the local hemostatic composition may further comprise additional saccharides and/or salts.
  • the additional saccharides are selected from sugar, maltose, invert sugar, glucose and fructose.
  • the additional saccharides raise viscosity of the local hemostatic composition of the invention and promote coagulation of plasma proteins and blood cells by absorbing moisture from the blood by osmotic pressure.
  • the salts of the invention are selected from calcium chloride (CaCh), sodium chloride (NaCI), ferric chloride (FeC ), potassium alum [KAI(S0 4 ) 2 ] and green vitriol (FeS0 4 ).
  • the salts comprised in the composition of the invention absorb moisture from the blood by osmotic pressure to let blood cells close, thereby reducing the coagulation time of blood.
  • the local hemostatic composition is in the form of liquid, and bleeding is stopped through pressing a wound region with medicinal cotton or gauze saturated by the same. It is also used to stop the hemorrhage of alimentary canal by the oral administration.
  • a second aspect of the present invention relates to use of the local hemostatic composition of the invention for stopping all the traumatic hemorrhage, intraoperative hemorrhage and hemorrhage of alimentary canal.
  • the profuse arterial hemorrhages such as the bleeding by injury or severance of abdominal aorta or arteria femoralis, not to mention capillary hemorrhage, are included.
  • the local hemostatic composition of the invention can stop the bleeding perfectly in a short time by forming the tough membranous structure in the region of profuse arterial hemorrhage. Also, it can stop the bleeding of alimentary canal by the oral administration.
  • the local hemostatic composition of the invention can be used in intraoperative hemorrhage.
  • the hemostatic agent of the invention comprising only N-acetylglucosamine and salt is more effective for stopping the bleeding in small blood vessels under a surgical operation.
  • the local hemostatic composition of the invention has the hemostatic effect in the water as well.
  • the local hemostatic composition of the invention does not produce ill effect on the wound and bleeding region, and has remarkable analgesic effect, anti-infective effect and tissue regeneration effect. Also, after stopping bleeding, there is no need of aftertreatments such as removal of the hemostatic composition around the wound.
  • the present invention provides the local hemostatic composition comprising N-acetylglucosamine to achieve the purpose of the invention.
  • the local hemostatic composition of the present invention is a hemostatic agent which can immediately stop bleeding in local region, such as all of the traumatic hemorrhage including the profuse arterial hemorrhages like the bleeding by injury or severance of abdominal aorta or arteria femoralis, hemorrhage of alimentary canal and intraoperative hemorrhage.
  • the present invention in a first aspect, provides a local hemostatic composition comprising N-acetylglucosamine and distilled water as a solvent.
  • N-acetylglucosamine content of the local hemostatic composition is 0.5 ⁇ 50% w/v.
  • N-acetylglucosamine (GlcNAc) of the present invention refers to N-acetyl-D- glucosamine.
  • N-acetylglucosamine reacts with blood plasma to make a membranous structure which can be adhered to organs and tissues.
  • the hemostatic composition of the invention makes a membranous structure while building up a boundary with blood in injured or severed vessel and the membranous structure adheres to injured or severed surface of vessel.
  • the membranous structure is so thick as to stand blood pressure, the bleeding is stopped.
  • the coagulating of blood in the inside of the membrane progresses regardless of membranous structure formation.
  • the membrane is gradually decomposed and absorbed in human body.
  • N-acetylglucosamine content of the local hemostatic composition of the invention is 3% to 30% w/v.
  • the local hemostatic composition further comprises one or more additional saccharides selected from sugar, maltose, invert sugar, glucose and fructose.
  • the additional saccharides content of the local hemostatic composition is 1% to 80% w/w, more preferably 10% to 70% w/w.
  • the additional saccharides raise viscosity of the local hemostatic composition of the invention and absorb moisture from blood by osmotic pressure to promote coagulation of plasma proteins and blood cells.
  • the local hemostatic composition further comprises one or more salts selected from calcium chloride (CaCI 2 ), sodium chloride (NaCI), ferric chloride (FeCI 3 ), potassium alum [KAI(S0 4 ) 2 ] and green vitriol (FeS04).
  • the salts content of the local hemostatic composition is 0.01 - 10% w/v, more preferably 0.1-7% w/v.
  • the salts comprised in the composition of the invention absorb moisture from blood by osmotic pressure to let blood cells close, thereby reducing the coagulation time of blood.
  • composition of the invention is prepared through dissolving N-acetylglucosamine in a suitable amount of distilled water of 80°C, mixing the additional saccharide or salt before getting cold, adding the distilled water up to total amount of 1000ml and then stirring for 30 minutes.
  • the local hemostatic composition of the invention is in the form of liquid.
  • the local hemostatic composition is prepared as a liquid and bleeding is stopped through pressing a wound region with medicinal cotton or gauze saturated by the same. It is also used for stopping the hemorrhage of alimentary canal by the oral administration. That is, the local hemostatic composition of the invention can make a good contact with the wound regardless of bleeding place and the form of a wound, thus stopping bleeding effectively.
  • the local hemostatic composition of the invention may further comprise general hemostatic agents such as adrenaline, carbazochrome sodium sulfonate or menadione sodium bisulfite, besides N-acetylglucosamine, additional saccharides, or salt. In that case, the local hemostatic composition can be more effective.
  • general hemostatic agents such as adrenaline, carbazochrome sodium sulfonate or menadione sodium bisulfite, besides N-acetylglucosamine, additional saccharides, or salt.
  • the local hemostatic composition can be more effective.
  • a second aspect of the invention relates to use of the local hemostatic composition of the invention for stopping all the traumatic hemorrhage, intraoperative hemorrhage and hemorrhage of alimentary canal.
  • the profuse arterial hemorrhages such as the bleeding by injury or severance of abdominal aorta or arteria femoralis, not to mention capillary hemorrhage, are included.
  • the bleeding is stopped through putting on the region of the traumatic hemorrhage with medicinal cotton or gauze saturated by the local hemostatic composition and pressing for some time.
  • the local hemostatic composition of the invention stops the bleeding effectively in a short time through forming tough membranous structure even in the region of profuse arterial hemorrhage.
  • the hemorrhage of alimentary canal mentioned in the present invention includes gastroduodenal hemorrhage, enterohemorrhage and the like. Such bleedings can be stopped effectively by the oral administration of the composition.
  • the intraoperative hemorrhage mentioned in the present invention includes not only capillary hemorrhage but also large vessel hemorrhage. Especially, it can effectively stop the bleeding in a brain surgery and there is no any negative influence.
  • the local hemostatic agent of the invention comprising only N-acetylglucosamine and salt, is more effective.
  • the local hemostatic composition of the invention has the hemostatic effect in the water as well.
  • the local hemostatic composition of the invention is a viscous liquid, is not readily mixed with water and can be substantially applied to the bleeding place with medicinal cotton or gauze saturated by the same. Thus, it can stop bleeding in water.
  • the local hemostatic composition of the invention does not produce ill effect on the wound and bleeding region, and has remarkable analgesic effect, anti-infective effect and tissue regeneration effect. Also, after stopping bleeding, there is no need of other treatments such as removing of the hemostatic composition around the wound.
  • compositions, the application method and the application examples of the experimental medicaments are provided for illustrative purposes only and should not be understood as limiting the present invention.
  • N-acetylglucosamine 20% w/v Sugar: 10% w/w Distilled water: Suitable amount Total volume: 1000ml
  • N-acetylglucosamine 3% w/v Glucose: 70% w/w Distilled water: Suitable amount Total volume: 1000ml
  • N-acetylglucosamine 12% w/v Invert sugar: 60% w/w Distilled water: Suitable amount Total volume: 1000ml
  • N-acetylglucosamine 12% w/v Fructose: 30% w/w Maltose: 30% w/w Distilled water: Suitable amount Total volume: 1000ml
  • N-acetylglucosamine 12% w/v Glucose: 10% w/w Sugar: 20% w/w Invert sugar: 30% w/w Distilled water: Suitable amount Total volume: 1000ml
  • N-acetylglucosamine 12% w/v Fructose: 30% w/w Maltose: 30% w/w
  • Example 1 The hemostatic effect on the bleeding in the arteria femoralis of white mouse
  • the experimental medicaments 1 ⁇ 9 are applied.
  • the saline solution is applied.
  • the experimental group is composed of 9 groups (80 white mice a group) of white mice weighing 130 to 180g without distinction of sex.
  • the control group is composed of one group (50 white mice a group) of white mice weighing 130-180g without distinction of sex.
  • left arteria femoralis of each of the white mice is severed and then medicinal cotton saturated by the local hemostatic composition (Experimental medicaments 1 -9) of the invention is applied to the experimental group and medicinal cotton saturated by 10% saline solution is applied to the control group.
  • the hemostatic effects are judged by whether bleedings are stopped after pressing a hemorrhage region for 10 seconds with medicinal cotton saturated by the local hemostatic composition of the invention or the 10% saline solution.
  • Table 3 The results are shown in Table 3.
  • the local hemostatic composition of the present invention is more effective against the bleeding by severance of the arteria femoralis of white mouse than the 10% saline solution.
  • Example 2 Hemostatic effect on the bleeding by severance of the arteria femoralis of hog
  • the experimental medicaments 7 and 8 are applied.
  • zeolite hemostatic To a control group 1, the zeolite hemostatic is applied. To a control group 2, Chitosan Wound Care Powder (Dezhou Harian Biological Technology Co., Ltd.) is applied.
  • the experimental group is composed of 3 groups (100 hogs a group) without distinction of sex.
  • the control group is composed of 2 groups (50 hogs a group) without distinction of sex.
  • arteria femoralis of each of the hogs is severed by a scalpel and then medicinal cotton saturated by the local hemostatic composition (Experimental medicaments 7-9) of the invention is applied to the experimental group and the zeolite hemostatic or Chitosan Wound Care Powder is applied to the control group.
  • the hemostatic effects of the experimental medicaments 7-9 are judged by whether bleeding is stopped after pressing a hemorrhage region with medicinal cotton saturated by the composition in the invention for 4 minutes and the hemostatic effects of the zeolite hemostatic or Chitosan Wound Care Powder are judged by whether bleeding is stopped in 4 minutes after they are applied to the hemorrhage region.
  • Table 4. Hemostatic effect on the bleeding by amputation of the arteria femoralis of hog
  • the local hemostatic composition of the present invention is far more effective against the bleeding by amputation of the arteria femoralis of hog than the zeolite hemostatic or Chitosan Wound Care Powder.
  • Example 3 Hemostatic effect on the bleeding by injury of the arteria femoralis of hog
  • the experimental medicaments 7 and 8 are applied.
  • the zeolite hemostatic is applied.
  • the experimental group is composed of 3 groups (100 hogs a group) without distinction of sex.
  • the control group is composed of 2 groups (50 hogs a group) without distinction of sex.
  • arteria femoralis of each of the hogs is cut 3 ⁇ 5mm in width or length by a scalpel and then medicinal cotton saturated by the local hemostatic composition (Experimental medicaments 7 or 8) of the invention is applied to the experimental group and the zeolite hemostatic or Chitosan Wound Care Powder is applied to the control group.
  • the hemostatic effects of the experimental medicaments 7-9 are judged by whether bleeding is stopped after pressing a hemorrhage region for 4 minutes with medicinal cotton saturated by the composition in the invention and the hemostatic effects of the zeolite hemostatic or Chitosan Wound Care Powder are judged by whether bleeding is stopped in 4 minutes after they are applied to the hemorrhage region.
  • the results are shown in Table 5.
  • the local hemostatic composition of the present invention is far more effective against the bleeding by injury of the arteria femoralis of hog than the zeolite hemostatic or Chitosan Wound Care Powder.
  • Example 4 Measurement of blood clot retraction rate of the local hemostatic composition of the invention
  • Experimental animal White mice weighing 120 ⁇ 150g (without distinction of sex) To an experimental group, the experimental medicament 7 is applied.
  • Experimental method The experimental animals are divided into experimental group and control group (10 white mice a group) and weighed. And the experimental group gets an injection of the experimental medicament 7 (0.45ml/100g (animal body weight)) in the abdominal cavity and the control group gets an injection of the saline solution (0.45ml/100g (animal body weight)) in the abdominal cavity. An hour later, 2ml of the blood is drawn from the orbital vein by using a capillary tube (length of 3cm, inside diameter of 1 mm) and then put in a test tube where a metal hook is placed.
  • a capillary tube length of 3cm, inside diameter of 1 mm
  • the blood clot stuck to the metal hook is drawn out from the test tube and then the blood clot retraction rate is determined by measuring the amount of blood sera remaining in the test tube.
  • the blood clot retraction rate of the experimental group is significantly higher than the same of the control group.
  • mice 10 white mice weighing 18 ⁇ 22g (without distinction of sex)
  • mice which were orally dosed with over 2.5ml of the local hemostatic composition per a kilogram of weight did not die.
  • the dorsal hair of rabbit was cut and then a wound was made in the size of 1.5 x 1.5cm.
  • the medicinal cotton of the same size as the wound, saturated by the local hemostatic composition of the present invention was put on the wound and then it was fixed by means of an adhesive tape.
  • composition of the present invention (Experimental medicament 7, 9)
  • Comparison medicament Adrenaline Usage: Bleeding region of each patient was pressed with the gauze saturated by the local hemostatic composition of the invention for 2 ⁇ 5 minutes.
  • Experimental medicament 9 was applied to capillary hemorrhage and experimental medicament 7 was applied to hemorrhage in medium or large vessel. Observation: Whether bleeding is stopped 2 ⁇ 5 minutes later and there is a re-bleeding or not was observed.
  • the hemostatic effect of the composition of the invention was significantly better than comparison medicament, adrenaline (within 2 minutes: 58.2%) in capillary hemorrhage and the hemostatic effect of the composition of the invention (within 4 ⁇ 5 minutes: 84.8%) was significantly better than comparison medicament, adrenaline.
  • the hemostatic effect of the composition of the invention is illustrated in detail with the application examples below.
  • composition of the invention was used for the hemostatic purpose in encephalomectomy in x x x hospital. After extraction of encephaloma, the gauze saturated by the composition of the invention was kept putting to the hemorrhage region for about 30 seconds. There was no re-bleeding after the operation. The patient was under the remote observation on aftereffects of the composition for a year and there was no aftereffect.
  • Application example 2 The composition of the invention, added adrenaline, was used in an operation on the tonsil in x x x hospital. The bleeding was stopped in 30 seconds and there was no re-bleeding after the operation. The wound healed up in a day.
  • Application example 3 The composition of the present invention was used as a hemostatic agent in gastroduodenal hemorrhage in x x x hospital.
  • composition of the present invention was applied to the gastroduodenal hemorrhage place directly using the endoscope and all the bleedings were stopped in about 40 seconds. From the next day, the patients had a dinner, but there was no re-bleeding.
  • composition of the present invention was applied to the gastroduodenal hemorrhage patient by oral administration to stop the bleeding. There was no re-bleeding.
  • Application example 4 When bleeding from the external wound (length of 3cm, depth of 8mm) in water, the medicinal cotton saturated by the local hemostatic composition of the present invention was applied to the wound and the bleeding was stopped in about 1 minute. The pain around the wound was stopped and the wound healed up within 2 days.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne une composition hémostatique locale comprenant de la N-acétylglucosamine dans une plage allant de 0,5 % à 50 % p/v et de l'eau distillée en tant que solvant. La composition hémostatique locale peut en outre comprendre un ou plusieurs saccharides supplémentaires choisis parmi le sucre, le maltose, le sucre inverti, le glucose et le fructose. La composition hémostatique locale peut en outre comprendre un ou plusieurs sels choisis parmi le chlorure de calcium (CaCl2), le chlorure de sodium (NaCl), le chlorure ferrique (FeCl3), l'alun de potassium [KAl(SO4)2] et du vitriol vert (FeSO4). La composition hémostatique locale de la présente invention peut être utilisée pour arrêter la totalité de l'hémorragie traumatique y compris une hémorragie artérielle sévère, une hémorragie peropératoire, une hémorragie du tube digestif, etc., et a également l'effet hémostatique dans l'eau.
PCT/KP2020/000050 2019-08-14 2020-07-25 Composition hémostatique locale WO2021029443A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202080058658.1A CN114269350B (zh) 2019-08-14 2020-07-25 局部止血组合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KP201910003754 2019-08-14
KP201910003754 2019-08-14

Publications (1)

Publication Number Publication Date
WO2021029443A1 true WO2021029443A1 (fr) 2021-02-18

Family

ID=74571267

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KP2020/000050 WO2021029443A1 (fr) 2019-08-14 2020-07-25 Composition hémostatique locale

Country Status (2)

Country Link
CN (1) CN114269350B (fr)
WO (1) WO2021029443A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1533774A (zh) * 2003-03-27 2004-10-06 �й������ž�������ҽ��ѧ N-乙酰氨基葡萄糖在制备治疗和控制物理化学因素致非特异性炎症的药物中的应用
CN1628675A (zh) * 2004-09-09 2005-06-22 吕益明 一种创伤药及其制备方法和使用方法
CN101209344A (zh) * 2006-12-28 2008-07-02 赵超英 高渗液组合物在制备促进伤口愈合的药物中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622834A (en) * 1993-12-01 1997-04-22 Marine Polymer Technologies, Inc. Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture
JPH10324633A (ja) * 1997-05-22 1998-12-08 Seikagaku Kogyo Co Ltd 血液凝固促進剤
CA2499463A1 (fr) * 2002-11-08 2004-05-27 The Brigham And Women's Hospital, Inc. Compositions et methodes de prolongement de la survie des plaquettes
WO2008103345A2 (fr) * 2007-02-19 2008-08-28 Marine Polymer Technologies, Inc. Compositions hémostatiques et régimes thérapeutiques
CN101229389A (zh) * 2007-12-29 2008-07-30 陈长昊 纳米固定化酶止血材料制备方法
RU2519026C2 (ru) * 2012-09-13 2014-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Уральская государственная медицинская академия Министерства здравоохранения и социального развития Российской Федерации" (ГБОУ ВПО УГМА Минздравсоцразвития России) Комбинированный гемостатический препарат для наружного применения

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1533774A (zh) * 2003-03-27 2004-10-06 �й������ž�������ҽ��ѧ N-乙酰氨基葡萄糖在制备治疗和控制物理化学因素致非特异性炎症的药物中的应用
CN1628675A (zh) * 2004-09-09 2005-06-22 吕益明 一种创伤药及其制备方法和使用方法
CN101209344A (zh) * 2006-12-28 2008-07-02 赵超英 高渗液组合物在制备促进伤口愈合的药物中的应用

Also Published As

Publication number Publication date
CN114269350A (zh) 2022-04-01
CN114269350B (zh) 2024-07-23

Similar Documents

Publication Publication Date Title
EP3228331B1 (fr) Produit hémostatique biocompatible et son procédé de préparation
US5037810A (en) Medical application for heparin and related molecules
Ersoy et al. Hemostatic effects of Microporous Polysaccharide Hemosphere® in a rat model with severe femoral artery bleeding
US9950091B2 (en) Composition and method for stopping hemorrhage, infection, and accelerating healing in various types of wound or burns
CN103349791B (zh) 一种新型微孔医用止血材料及其制备方法
US4879282A (en) Medical application for heparin and related molecules
EP2233157A1 (fr) Matériau spongieux biocompatible à l'amidon dénaturé
RU2438654C1 (ru) Гидрогелевая композиция для лечения ожогов
CN102526795A (zh) 壳聚糖基止血海绵及其制备方法
US20100298264A1 (en) Biodegradable and water-soluble hemostatic material and a method for preparing the same
CN101313915A (zh) 透明质酸及其盐、交联透明质酸及其盐在制备治疗或预防海泡伤药物中的应用
Yan et al. Synthesis and properties of poly (DEX-GMA/AAc) microgel particle as a hemostatic agent
JP6807922B2 (ja) 止血、組織障壁、創傷治癒、および美容術のための生体適合性カルボキシメチルセルロースマトリックス（ｂｃｍ）
WO2016155749A1 (fr) Produit hémostatique et cicatrisant
CN111617310B (zh) 一种止血海绵及其制备方法和应用
CN107496973B (zh) 一种快速止血壳聚糖海绵垫创可贴及其制备方法
CN106902383B (zh) 一种改性葡聚糖修饰的纳米凝胶止血材料及其制备和应用
CN112870430A (zh) 基于天然多糖的复合凝胶止血粉、其制备方法及应用
CN105727345A (zh) 一种可吸收性止血膜材料及其制备方法
CN104307031A (zh) 一种皮肤外用修复材料的制备方法及用途
WO2021029443A1 (fr) Composition hémostatique locale
CN113134112B (zh) 一种快速吸液膨胀型复合压缩止血海绵及其制备方法
CN106822986B (zh) 一种壳聚糖-琼胶低聚糖多孔球珠止血材料的制备方法
CN107715167A (zh) 作为骨蜡替代物的壳聚糖基止血糊剂及制备方法
WO2017060821A1 (fr) Composition hémostatique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20851846

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 05.07.2022)

122 Ep: pct application non-entry in european phase

Ref document number: 20851846

Country of ref document: EP

Kind code of ref document: A1